Emily Luisa Hill Sells 11,448 Shares of Replimune Group (NASDAQ:REPL) Stock

Key Points

• CFO Emily Luisa Hill sold 11,448 Replimune shares at an average price of $12.97, generating $148,480.56. The filing said the sale covered tax-withholding obligations tied to vested equity awards, and she retained 225,108 shares.
• Replimune shares rose 11.6% to $15.24, despite the company reporting a quarterly loss of $0.76 per share that missed analysts’ estimates. The company also priced a $150 million offering to fund its oncology pipeline and RP1 development.
• Analyst sentiment is broadly positive, with MarketBeat reporting a “Moderate Buy” consensus and an average $11.86 price target, although the company faces ongoing securities-class-action allegations concerning RP1 disclosures and FDA study-design concerns.

Replimune Group, Inc. (NASDAQ:REPL - Get Free Report) CFO Emily Luisa Hill sold 11,448 shares of the business's stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $12.97, for a total transaction of $148,480.56. Following the completion of the transaction, the chief financial officer directly owned 225,108 shares of the company's stock, valued at $2,919,650.76. This trade represents a 4.84% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Replimune Group Stock Up 11.6%

Replimune Group stock traded up $1.59 during mid-day trading on Wednesday, reaching $15.24. 8,269,132 shares of the company were exchanged, compared to its average volume of 5,046,735. The company has a debt-to-equity ratio of 0.63, a quick ratio of 4.79 and a current ratio of 4.79. The firm has a market cap of $1.28 billion, a P/E ratio of -4.51 and a beta of 0.88. The business has a fifty day moving average of $10.34 and a 200 day moving average of $7.64. Replimune Group, Inc. has a 12-month low of $1.50 and a 12-month high of $15.68.

Replimune Group (NASDAQ:REPL - Get Free Report) last announced its quarterly earnings results on Monday, June 29th. The company reported ($0.76) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.66) by ($0.10). Research analysts anticipate that Replimune Group, Inc. will post -2.45 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

REPL has been the subject of several analyst reports. Weiss Ratings lowered shares of Replimune Group from a "sell (d-)" rating to a "sell (e+)" rating in a research report on Tuesday. Wedbush raised shares of Replimune Group from a "neutral" rating to an "outperform" rating and set a $12.00 price objective on the stock in a research report on Friday, August 7th. Leerink Partners upgraded shares of Replimune Group from a "market perform" rating to an "outperform" rating and boosted their price objective for the stock from $11.00 to $17.00 in a research note on Tuesday, August 4th. Wolfe Research raised shares of Replimune Group to an "outperform" rating in a research report on Tuesday, August 4th. Finally, Cantor Fitzgerald restated an "overweight" rating on shares of Replimune Group in a research note on Wednesday. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $11.86.

Replimune Group News Summary

Here are the key news stories impacting Replimune Group this week:

• Positive Sentiment: $150 million offering priced: Replimune priced a $150 million underwritten public offering, providing additional cash to support development of its oncology pipeline and RP1. The financing appears to have reassured investors about the company’s liquidity and ability to fund operations. Replimune Announces Pricing of $150 Million Underwritten Offering
• Neutral Sentiment: Insider transactions were primarily tax-related: CEO Sushil Patel, CFO Emily Hill, CAO Andrew Schwendenman and insider Konstantinos Xynos sold shares totaling approximately $1.01 million. The filings state that the sales covered tax-withholding obligations tied to vested equity awards, while each executive retained a substantial position; therefore, the transactions provide limited evidence of a change in business confidence. SEC insider transaction filing
• Negative Sentiment: Several law firms publicized a securities class action: The lawsuits cover investors who purchased Replimune securities between October 20, 2025, and April 10, 2026. The allegations claim the company misled investors about the efficacy and commercial viability of RP1 and failed to disclose unresolved FDA study-design concerns. CEO Sushil Patel and CFO Emily Hill are named as individual defendants, and the lead-plaintiff deadline is October 5, 2026. The notices increase legal and reputational uncertainty, although the allegations have not been proven. REPL Class Action Reminder Levi and Korsinsky class action notice

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. ProShare Advisors LLC boosted its holdings in Replimune Group by 10.3% in the fourth quarter. ProShare Advisors LLC now owns 16,116 shares of the company's stock worth $157,000 after acquiring an additional 1,505 shares in the last quarter. JPMorgan Chase & Co. increased its holdings in shares of Replimune Group by 4.7% during the third quarter. JPMorgan Chase & Co. now owns 38,016 shares of the company's stock valued at $159,000 after acquiring an additional 1,712 shares in the last quarter. Ballentine Partners LLC increased its holdings in shares of Replimune Group by 7.8% during the fourth quarter. Ballentine Partners LLC now owns 23,665 shares of the company's stock valued at $230,000 after acquiring an additional 1,721 shares in the last quarter. BNP Paribas Financial Markets raised its position in shares of Replimune Group by 37.5% in the 2nd quarter. BNP Paribas Financial Markets now owns 6,889 shares of the company's stock valued at $64,000 after purchasing an additional 1,879 shares during the last quarter. Finally, Walleye Capital LLC raised its position in shares of Replimune Group by 3.2% in the 1st quarter. Walleye Capital LLC now owns 71,592 shares of the company's stock valued at $548,000 after purchasing an additional 2,192 shares during the last quarter. 92.53% of the stock is owned by institutional investors and hedge funds.

Replimune Group Company Profile

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company's proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune's lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source